We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Indian drug firm Glenmark Pharmaceuticals has signed a deal with U.S.-based InvaGen to market generic versions of seven brand drugs with a current annual U.S. market of $4.1 billion, in Glenmark’s latest move to bolster its position in the U.S. market.
Mylan Laboratories has entered into a supply agreement with a Johnson & Johnson (J&J) subsidiary for J&J’s extended-release incontinence drug Ditropan XL, pending a final court ruling on the firms’ patent dispute.
Eli Lilly and Alkermes have signed a joint agreement to develop and commercialize inhaled formulations of parathyroid hormone (PTH), an osteoporosis treatment.
Amgen, the world’s largest biotechnology company, will acquire drug development partner Abgenix for $2.2 billion, allowing Amgen to acquire a promising experimental cancer drug that may spell trouble for Bristol-Myers Squibb’s (BMS) and ImClone’s competing drug Erbitux.
Roche has pared a list of 200 potential Tamiflu partners down to 12 with whom it plans to begin “in-depth” negotiations for sub-licensing agreements for the highly sought-after antiviral.
The boards of Alliance Medical and Vanguard Medical Concepts recently approved an agreement that would merge the two leading third-party reprocessors of single-use medical devices (SUDs).
AstraZeneca has agreed to pay up to $1.3 billion under a pair of collaboration agreements to gain access to investigational compounds targeting Alzheimer’s disease and atherosclerosis.